Loading...
Market
How will lenacapavir's effectiveness compare across demographic groups by end of 2024?
2
Resolution / Starting Odds
More effective in men • 25%
More effective in gender-diverse individuals • 25%
Equally effective in both groups • 25%
Insufficient data for conclusion • 25%
Published studies and trial results
Story
Gilead's Phase 3 Trial Led by Emory Shows Lenacapavir Reduces HIV Risk by 96%
Nov 27, 2024, 10:21 PM
Gilead Sciences has announced the publication of the full results of its Phase 3 PURPOSE-2 clinical trial in the New England Journal of Medicine. The trial, led by Emory University, evaluated the efficacy of twice-yearly lenacapavir injections for HIV prevention in men and gender-diverse individuals. Results showed that lenacapavir significantly reduced the risk of HIV infection by 96%, outperforming daily oral PrEP in adherence and effectiveness. The study demonstrated that lenacapavir had a lower incidence of HIV infection compared to both the background incidence and the incidence with emtricitabine–tenofovir disoproxil fumarate.
View original story
Similar markets
Reduction by less than 5% • 25%
Reduction by 5% to 10% • 25%
Reduction by 10% to 15% • 25%
Reduction by more than 15% • 25%
Less than 10% • 25%
10%-30% • 25%
31%-50% • 25%
More than 50% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Higher adoption than oral PrEP • 25%
Equal adoption to oral PrEP • 25%
Lower adoption than oral PrEP • 25%
Data not sufficient to determine • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%